Company Overview
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +469.52% |
| 6 Months: | +13.90% |
| 3 Months: | +55.32% |
| 1 Month: | +0.84% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.78 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ANTX AN2 Therapeutics, Inc. PHARMA | 5.98 | -5.70 | $225.66M | 0.00% | -71.59% | -50.12% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -2.05M | -5.00M | -6.93M | -7.68M | -10.33M | -11.77M | -16.04M | -16.60M | -18.18M | -18.30M | -15.88M | -14.01M | -11.54M | -7.22M | -10.04M | -10.55M |
| Net Income | -2.05M | -5.01M | -6.94M | -7.66M | -10.12M | -11.34M | -15.32M | -15.80M | -16.71M | -16.62M | -14.44M | -12.75M | -10.65M | -6.46M | -9.35M | -10.03M |
| Diluted EPS | - | -2.62 | -3.35 | -2.98 | -0.53 | -0.59 | -0.79 | -0.81 | -0.65 | -0.56 | -0.48 | -0.43 | -0.35 | -0.21 | -0.31 | -0.29 |
| R&D Expense | 1.65M | 3.85M | 5.34M | 5.63M | 6.70M | 7.43M | 11.98M | 13.54M | 14.43M | 14.65M | 12.15M | 8.29M | 7.69M | 3.20M | 7.00M | 6.74M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Income | -21.57M | -42.26M | -69.64M | -56.79M | -38.11M |
| Net Income | -21.54M | -40.96M | -64.73M | -51.32M | -35.17M |
| Diluted EPS | -10.64 | -2.79 | -2.74 | -1.72 | -1.16 |
| R&D Expense | 16.16M | 28.51M | 54.87M | 40.49M | 24.77M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 102.56M | 138.74M | 92.09M | 61.95M |
| Current Assets | - | - | 98.62M | 110.51M | 86.26M | 59.94M |
| Cash & Equivalents | - | - | 27.22M | 15.65M | 21.35M | 19.94M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Total Liabilities | - | - | 7.19M | 14.04M | 10.24M | 8.89M |
| Current Liabilities | - | - | 7.19M | 14.04M | 10.24M | 8.72M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | 0 | 53.00K | 0 | - | - |
| Total Equity | -20.32M | - | 95.37M | 124.70M | 81.85M | 53.06M |
| Shares Outstanding | - | - | 19.40M | 29.74M | 29.92M | 27.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -20.48M | -33.46M | -53.29M | -49.26M | -29.83M |
| Investing Cash Flow | -50.02M | -21.77M | -43.28M | 54.59M | 28.31M |
| Financing Cash Flow | 78.53M | 70.36M | 84.99M | 372.00K | 113.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -42.9% | -51.9% | -62.7% | -66.3% |
| ROCE % | - | -44.3% | -55.8% | -69.4% | -71.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vivo Capital, LLC | 8.36% | 3.15M | $15.93M |
| 2 | Commodore Capital Lp | 7.77% | 2.93M | $14.82M |
| 3 | Millennium Management Llc | 6.14% | 2.32M | $11.71M |
| 4 | Blackrock Inc. | 4.41% | 1.67M | $8.41M |
| 5 | Spruce Street Capital LP | 4.40% | 1.66M | $8.39M |
| 6 | Almitas Capital LLC | 3.89% | 1.47M | $7.42M |
| 7 | Vanguard Capital Management LLC | 3.28% | 1.24M | $6.26M |
| 8 | Adage Capital Partners GP L.L.C. | 2.65% | 1.00M | $5.05M |
| 9 | Citadel Advisors Llc | 2.52% | 952.00K | $4.81M |
| 10 | Boxer Capital Management, LLC | 1.98% | 749.03K | $3.78M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ANTX
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
MENLO PARK, Calif., August 24, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the appointment o…
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif., August 11, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, …
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
MENLO PARK, Calif., June 04, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results fro…
Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight
The nontuberculous mycobacterial infections Market is expected to experience notable growth in the coming years, driven by the increasing prevalence and improved diagnosis of NTM infections, particularly among aging populations and individu…
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
MENLO PARK, Calif., August 31, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, …
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
AN2 Therapeutics (ANTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ANTX — Frequently Asked Questions
What is the current share price of AN2 Therapeutics, Inc. (ANTX)?
As of 2026-09-19 21:16 PDT, AN2 Therapeutics, Inc. (ANTX) trades at $5.98 on NasdaqGS. Its 52-week range is $1.03 to $6.28.
What is the market capitalisation of ANTX?
AN2 Therapeutics, Inc. (ANTX) has a market capitalisation of $225.66M on NasdaqGS.
What is the P/E ratio of ANTX?
ANTX trades at a trailing price-to-earnings (P/E) ratio of -5.70. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.74.
What is the return on equity (ROE) of ANTX?
ANTX has a return on equity (ROE) of -50.12%. Its return on capital employed (ROCE) is -71.59%.
Is ANTX a good stock to buy?
This page provides a data-driven analysis of AN2 Therapeutics, Inc. (ANTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.